Maintaining the Cold Chain - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Maintaining the Cold Chain


Pharmaceutical Technology



Hallie Forcinio
Drugs shipped by truck, train, ship, or aircraft can be subjected to temperatures ranging from far below zero to well above 100 F, sometimes during the same trip. Exposure to these extremes can be disastrous for temperature-sensitive products. In less severe cases, shelf life can be shortened. In worst-case scenarios, product can be ruined, resulting in losses that can add up to hundreds of thousands of dollars.

To help pharmaceutical manufacturers protect temperature-sensitive products during shipment, the Parenteral Drug Association (Bethesda, MD, http://www.pda.org/) has published a guidance document drafted by its Cold Chain Management Task Force and reviewed by technical experts from the industry. Several years in the making, "Technical Report No. 39: Cold Chain Guidance for Medicinal Products: Maintaining the Quality of Temperature-Sensitive Medicinal Products through the Transportation Environment" discusses how to develop protective packages and systems to provide "thermally controlled transportation" (1). The guidance also aligns with the Center for Drug Evaluation and Research's (Bethesda, MD, http://www.fda.gov/) "General Principles of Process Validation: Component Qualification (CQ), Operating Qualification (OQ), and Performance Qualification (PQ)."


Multiple layers of CrioMED Plus insulated bag protect product inside from temperature extremes.
Stability studies. Determining how to protect products depends heavily on stability studies. Actual studies are needed because "Long-term storage or label storage temperatures may be different from short-term shipping/distribution temperatures" (1). Three types of studies should be undertaken to address temperature control issues: long-term, accelerated, and temperature excursion. Temperature excursion studies are particularly important because it's not uncommon for shipments to be exposed to conditions outside anticipated extremes because of weather, delays, equipment malfunctions, mishandling, or other causes.

All levels of packaging from primary container–closures to distribution packaging affect the product's thermal stability and should be included in the testing program. In fact, "The more empty space within the secondary package not utilized by the thermal mass of the product, the more difficult it is to control the system thermally" (1).

Developing a protective system. The development of a thermally protective system begins with the creation of a functional requirements document and the specification of components such as insulated containers and refrigerants. The functional requirements document includes the critical parameters related to the packaging and transport systems such as the types of vehicle, routes, trip duration, product stability, likely temperature range of exposure, and packaging. The component specification is a detailed description of requirements for features such as material composition, mechanical characteristics, dimensions, printing, storage, sampling, weight, insulation, calibration limits, fragility limits, and shock and vibration limits.

Design testing is the next step. "The outcome of design testing assures a high confidence for successful operational qualification of a specific package or system," the report explains (1).

Then, qualification testing is "performed using the designated configuration to provide assurance that product quality is maintained during transport." Both design and qualification testing results should be documented in a formal report (1).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here